Press Release

July 31, 2026 To, To, National Stock Exchange of India Limited, BSE Limited, “Exchange Plaza”, Corporate Relationship Department, 5th Floor, Plot No. C/1, G Block, 2nd Floor, New Trading Ring, Bandra- Kurla Complex Bandra (East), Mumbai P.J. Towers, Dalal Street, – 400 051 Mumbai – 400 001 Scrip Name: GLENMARK Scrip Code: 532296 ISIN: INE935A01035 ISIN: INE935A01035 Our Reference No. 37/26-27 Our Reference No. 37/26-27 Dear Sir/ Madam, Sub: Press Release and Management Discussion & Analysis Pursuant to regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, we are enclosing herewith the Press Release and Management Discussion & Analysis of the Company for the First Quarter ended June 30, 2026. You are requested to take the same on record. Thanking You. Yours faithfully, For Glenmark Pharmaceuticals Limited Rashmi Khandelwal Company Secretary & Compliance Officer ACS - 28839 Encl: As above Glenmark Pharmaceuticals Limited Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E:complianceofficer@glenmarkpharma.com Glenmark Pharmaceuticals Announces Q1 FY27 Results Highlights • India Formulations revenue up by 15.5% YoY at Rs. 14,321 million • North America revenue grew by 41.1% YoY to Rs. 10,974 million (Includes deferred out- licensing income recognition for ISB 2001) • Europe revenue grew by 11.9% YoY to Rs.7,472 million • Emerging Markets revenue up by 27.7% YoY to Rs. 7,304 million • EBITDA of Rs. 8,048 million, 38.6% YoY growth, with an EBITDA margin of 20.03% • Profit After Tax (PAT) of Rs. 4,828 million, with PAT margin of 11.8% Mumbai, India, July 31, 2026: Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, today announced its financial results for the first quarter ended June 30, 2026. For the first quarter of FY 2027, Glenmark’s consolidated revenue was Rs. 40,185 million as against Rs. 32,644 million in the corresponding quarter last year, recording an overall growth of 23.1% YoY. EBITDA was Rs. 8,048 million in the quarter ended June 30, 2026, registering 38.6% YoY growth and an EBITDA margin of 20.03%. Profit After Tax (PAT) for the quarter was Rs. 4,828 million, with a PAT margin of 11.8%. Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd. said, “We have started FY2027 with broad-based growth across our key markets, reflecting strong execution and the resilience of our business. India continued to outperform the market, North America delivered robust underlying growth driven by our first-to- market respiratory launches, and Emerging Markets sustained strong momentum, underscoring the strength of our diversified global business. The results reinforce the direction of Glenmark’s next phase: strengthening our core businesses while expanding our differentiated specialty and innovation-led platforms. With RYALTRIS® continuing to grow globally, WINLEVI® gaining traction across Europe, and further progress across our oncology portfolio and IGI’s pipeline, we remain focused on disciplined execution, sustainable and profitable growth and creating long-term value.” About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: Akhila Natarajan | mediarelations@glenmarkpharma.com Adfactors PR | glenmark.ihcp@adfactorspr.com Management Discussion & Analysis for the First Quarter of FY 2026-27 Revenue Figures – Consolidated (In Rs. million) For the first quarter ended June 30 FY 2027 FY 2026 Growth (%) India 14,321 12,399 15.5% North America# 10,974 7,780 41.1% Europe 7,472 6,678 11.9% Emerging Markets## 7,304 5,721 27.7% Total 40,071 32,578 23.0% Other Revenue 114 66 72.4% Consolidated Revenue 40,185 32,644 23.1% # North America revenue for Q1 FY27 includes deferred out-licensing income recognition for ISB 2001 ## Russia + CIS (RCIS), Latin America (LATAM), Middle East and Africa (MEA), Asia-Pacific (APAC) Average conversion rate in 3M FY 2026-27 considered as INR 94.53 / USD 1.00 Average conversion rate in 3M FY 2025-26 considered as INR 85.54 / USD 1.00 USD figures are only indicative Management Discussion & Analysis: Q1 FY 2026-27 1 Review of Operations for the Quarter ended June 30, 2026 For the first quarter of FY27, Glenmark’s consolidated revenue from operations was at Rs. 40,185 million (USD 425.1 million) as against Rs. 32,644 million (USD 381.6 million) in the corresponding quarter last year, recording overall year-on-year (YoY) growth of 23.1%. FORMULATION BUSINESS Glenmark’s global formulation business is spread across Branded, Generics, and OTC segments in the therapy areas of Dermatology, Respiratory and Oncology, along with strong regional/country-specific presence in other therapeutic areas like Cardiac, Diabetes and Oral Contraceptives. INDIA Sales from the formulation business in India for the first quarter of FY27 was at Rs. 14,321 million (USD 151.5 million) as against Rs. 12,399 million (USD 145 million) in the corresponding quarter last year, recording a growth of 15.5%. Glenmark continued to significantly outperform the IPM in terms of secondary sales as per IQVIA. Glenmark’s India formulation business recorded a growth of 18.1% in Q1 FY27 and 14.3% as per MAT June 2026, compared to IPM growth of 12.2% in Q1 FY27 and 10.0% in MAT June 2026. Glenmark continued to sustain strong growth in its core therapy areas like Dermatology, Respiratory, Cardiac and Oncology. VALUE GROWTH % VALUE GROWTH % (APR’26 - JUN'26) (MAT JUN'26) SUPERGROUP IPM GLENMARK IPM GLENMARK CARDIAC 16.2 19.1 14.8 17.4 DERMATOLOGY 10.3 14.4 7.3 9.1 RESPIRATORY 10.5 13.4 11.0 13.6 DIABETES 15.5 -3.7 13.4 -4.4 Glenmark’s India business is ranked 13th with a market share of 2.37% as per IQVIA MAT June 2026. The Company has 11 brands in the IPM Top 300 Brands in the country as of IQVIA MAT June 2026. In terms of core therapy areas, Glenmark is ranked 2nd in Dermatology, 3rd in Respiratory and 4th in the Cardiac segment as per IQVIA MAT June 2026. Management Discussion & Analysis: Q1 FY 2026-27 2 GLENMARK MARKET SHARE % GLENMARK MARKET SHARE % SUPERGROUP MAT JUN'25 MAT JUN'26 CARDIAC 6.0 6.1 DERMATOLOGY 8.3 8.4 RESPIRATORY 5.8 6.0 DIABETES 1.2 1.0 TEVIMBRA® (TISLELIZUMAB) & BRUKINSA® (ZANUBRUTINIB) PARTNERED WITH BEONE • Glenmark launched Tislelizumab and Zanubrutinib in India under the respective brand names TEVIMBRA® and BRUKINSA® in Q1 FY26 • In a short period of time, the two brands have seen a very strong uptake in the market as a differentiated treatment option available for patients across multiple solid tumors and hematological malignancies. • The Company expects these two brands to gain further momentum and meaningfully contribute to the India business growth over the next 2-3 years. NEBZMART® GFB Smartules® / GLENMARK AIRZ® FB Smartules® • In Q3 FY26, Glenmark announced the launch of NEBZMART® GFB Smartules® and Glenmark AIRZ® FB Smartules®, the world’s first nebulized, fixed-dose triple therapy for the treatment of Chronic Obstructive P [Showing first 8,000 characters — download PDF for full document]